New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III
The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.
The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.
What's Your Reaction?
